
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
Results from the Phase II ALPACA trial (NCT05565742) published by The New England Journal of Medicine show that lepodisiran (Eli Lilly) produced significant and sustained reductions in lipoprotein(a) levels, demonstrating its potential to address this …